0000905718-15-000287.txt : 20150309 0000905718-15-000287.hdr.sgml : 20150309 20150309161413 ACCESSION NUMBER: 0000905718-15-000287 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20150309 DATE AS OF CHANGE: 20150309 EFFECTIVENESS DATE: 20150309 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Integral Ad Science, Inc. CENTRAL INDEX KEY: 0001473705 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-235477 FILM NUMBER: 15685345 BUSINESS ADDRESS: STREET 1: 95 MORTON STREET, 8TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 BUSINESS PHONE: 646-278-4871 MAIL ADDRESS: STREET 1: 95 MORTON STREET, 8TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 FORMER COMPANY: FORMER CONFORMED NAME: Ad Safe Media, Ltd. DATE OF NAME CHANGE: 20091002 D 1 primary_doc.xml X0707 D LIVE 0001473705 Integral Ad Science, Inc. 95 MORTON STREET, 8TH FLOOR NEW YORK NY NEW YORK 10014 646-278-4871 DELAWARE None Ad Safe Media, Ltd. Corporation true Scott Knoll c/o Integral Ad Science, Inc. 95 Morton Street, 8th Floor New York NY NEW YORK 10014 Executive Officer Director Jeff Fagnan c/o Integral Ad Science, Inc. 95 Morton Street, 8th Floor New York NY NEW YORK 10014 Director Eric Carlborg c/o Integral Ad Science, Inc. 95 Morton Street, 8th Floor New York NY NEW YORK 10014 Director Don Epperson c/o Integral Ad Science, Inc. 95 Morton Street, 8th Floor New York NY NEW YORK 10014 Director Ben Dahl c/o Integral Ad Science, Inc. 95 Morton Street, 8th Floor New York NY NEW YORK 10014 Director Rick Okin c/o Integral Ad Science, Inc. 95 Morton Street, 8th Floor New York NY NEW YORK 10014 Executive Officer Michael Iantosca c/o Integral Ad Science, Inc. 95 Morton Street, 8th Floor New York NY NEW YORK 10014 Executive Officer Other Technology Decline to Disclose 06b false 2015-02-27 false true true At closing, our wholly owned subsidiary merged with and into Veenome, Inc. ("Veenome") and Veenome merged with and into another wholly owned subsidiary. 0 4000000 4000000 0 The stockholders of Veenome will receive cash consideration and up to 229,906 shares of our common stock as more fully set forth in the offering materials. false 38 0 0 0 false Integral Ad Science, Inc. /s/ Kristin Leary Kristin Leary SVP, Finance 2015-03-09